Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Globe Newswire (Fri, 11-Sep 8:00 AM ET)
Clearmind Medicine Inc. GAAP EPS of -$0.57
Seeking Alpha News (Thu, 10-Sep 4:19 PM ET)
Globe Newswire (Tue, 8-Sep 7:42 AM ET)
Globe Newswire (Fri, 4-Sep 7:32 AM ET)
Globe Newswire (Tue, 1-Sep 7:37 AM ET)
Globe Newswire (Mon, 24-Aug 8:51 AM ET)
Globe Newswire (Mon, 24-Aug 8:03 AM ET)
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Globe Newswire (Thu, 13-Aug 7:36 AM ET)
Globe Newswire (Tue, 11-Aug 8:05 AM ET)
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Globe Newswire (Thu, 6-Aug 8:00 AM ET)
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
Clearmind Medicine - Common Shares trades on the NASDAQ stock market under the symbol CMND.
As of September 15, 2026, CMND stock price declined to $0.88 with 66,583 million shares trading.
CMND has a beta of 1.58, meaning it tends to be more sensitive to market movements. CMND has a correlation of 0.01 to the broad based SPY ETF.
CMND has a market cap of $1.31 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CMND traded as high as $4,140.04 and as low as $.85.
CMND has underperformed the market in the last year with a price return of -99.8% while the SPY ETF gained +16.3%. CMND has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -73.7% and -54.6%, respectively, while the SPY returned +2.3% and -1.3%, respectively.
CMND support price is $.86 and resistance is $1.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMND shares will trade within this expected range on the day.
